Introduction
Bladder cancer is the fifth most common malignancy in men and seventh in women. Over 90% of bladder cancers are transitional cell carcinoma, and in about 20-25% of patients, the disease has invaded the bladder musculature at presentation (Koss, 1979; Cutler et al., 1982; Lutzeyer et al., 1982; Stein et al., 2001) . Several genetic lesions that provide cues for cell transformation, increased cell growth, migration and invasion in bladder cancer have been identified. These include mutations or alterations in expression of p53, p16, pRb, p21, c-erb B-2, MMP-2 and -9, uPAR, PD-ECGF and bFGF (Chatterjee et al., 2004; Gontero et al., 2004; Buscarini et al., 2005) . Cumulative increase in these genetic defects also provides prognostic assessment for disease outcome. Despite progress in the understanding of bladder tumor biology, progress in advancing therapy is lagging such that median survival of patients with metastatic or recurrent disease continues to be just over a year (Logothetis et al., 1990; Loehrer et al., 1992; von der Maase et al., 2000; Sternberg et al., 2001) . There is thus a need for the identification and application of novel therapeutic targets in bladder cancer.
EphB4 is a member of the largest known family of receptor protein tyrosine kinases, which plays an important role in angiogenesis and vascular network assembly (Pasquale, 1997; Gerety et al., 1999; Holder and Klein, 1999; Tickle and Altabef, 1999) . EphB4 is normally expressed on venous endothelial cells, while its exclusive ligand, EphrinB2, is expressed on arterial endothelial cells as a transmembrane protein as well. Aberrant expression of EphB4 has been observed in several tumor cell types, although its role in tumor cell biology remains to be fully elucidated (Andres et al., 1995; Berclaz et al., 1996 Berclaz et al., , 2003 Stephenson et al., 2001; Takai et al., 2001) . EphB4 activation leads to a number of downstream effects, which influence cell attachment, migration and interaction with ligand-expressing cells (Adams et al., 1999; Oates et al., 1999; O'Leary and Wilkinson, 1999; Steinle et al., 2002) . Inhibition of binding of EphB4 to its ligand prevents downstream effects of receptor activation. In this report, we show that EphB4 is frequently overexpressed in bladder cancer. Furthermore, EphB4 provides survival advantage to the tumor cells, and is regulated by growth factors and tumor suppressor proteins. Targeting EphB4 is an ideal, novel and viable option as therapy in bladder cancer.
Results
Functional EphB4 is overexpressed in bladder cancer cell lines and tumor specimens EphB4 expression was examined by Western blot in nine bladder cancer cell lines. All cell lines examined express EphB4 at variable levels. The highly invasive and highgrade tumor cell lines TCCSUP and HT1376 cells had maximal expression of EphB4 (Figure 1a , top lane). Quantitative PCR was used to assess EPHB4 gene copy number in the cell lines. The locus of EPHB4 gene was amplified in 3/9 (33%) cell lines (identified with an asterisk in Figure 1a ) with a maximal 8.6-fold amplification in the invasive TCC cell line 5637, which also expresses relatively high levels of EphB4 protein. HT1376, the cell line with highest EphB4 protein expression, had a 3.7-fold amplification of the gene locus. The overexpressed receptor is functional. Treatment of 5637 cells with clustered EphrinB2/Fc for 15 min led to receptor phosphorylation (Figure 1b) , while clustered Fc alone had no effect. Receptor expression could be efficiently knocked down using specific siRNA and antisense oligodeoxynucleotide (ODN) molecules (see below). Concomitant to fall in receptor levels in 5637 cells following treatment for 48 h To ascertain the clinical correlation of the observed overexpression of EphB4 in cell lines, we prospectively collected fresh tumor and adjacent normal tissue from patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Tissue analysis included immunohistochemical staining of frozen sections, and quantitative estimation of protein levels and EPHB4 gene copy number. A total of 15 such cases were studied. EphB4 protein levels were elevated in 14 of 15 tumors (93%) by Western blotting and levels varied from 0.6-to 21.7-fold with a mean sevenfold higher expression in tumor specimens compared to normal urothelium ( Figure 1c , HUVEC was loaded as positive control for EphB4). To define the tissue distribution of EphB4, immunohistochemical staining was performed on frozen tumor sections. In eight of 15 specimens (53%), EphB4 expression could be demonstrated by immunohistochemistry. Tumors that had higher EphB4 expression levels on Western blotting also had stronger signals on staining. Western blot thus provides higher sensitivity than immunostaining. EphB4 expression was seen exclusively in the neoplastic urothelium (tumor) while adjacent stroma was uniformly negative (Figure 1d ). In a majority of positive sections, EphB4 signal was restricted to the cell membrane ( Figure 1d , Case 3 tumor section on right and Case 4). EphB4 expression was also seen in the vascular endothelium, presumably of venous lineage, on both tumor sections (note serial sections stained for CD31 to delineate vessels, Figure 1d , Case 1 and Case 2) and normal urothelium (Figure 1d , Case 3, normal section on left). Ongoing studies in a cohort of 200 patients will allow us to define the relationship between EphB4 levels and stage and grade of the disease.
EphB4 gene amplification was determined from the DNA of tumor samples. EPHB4 gene locus was amplified to four or more copy numbers in four (27%) cases. Thus, clinically localized tumor shows gene amplification in about a fourth of the cases.
EphrinB2 is expressed in bladder cancer cell lines and tumor specimens
We evaluated the expression of EphrinB2 in bladder cancer cell lines and tumor specimens by Western blotting. Eight out of nine (89%) cell lines studied ( Figure 1a , third panel) and all tumor specimens expressed EphrinB2 (Figure 1c , middle panel). Also, higher levels of expression of EphrinB2 were noted in tumor specimens compared to adjacent normal urothelium in 13 of 15 (87%) cases. FACS analysis of 5637 cells confirmed that individual tumor cells expressed both EphrinB2 and EphB4 (data not shown).
When bladder cancer cell lines that coexpress EphB4 and EphrinB2 were cultured in the presence of 10% fetal bovine serum (FBS), there was a basal level of phosphorylation of EphB4 (Figure 1a , second panel). It is likely that EphB4 expressed on bladder cancer cell lines is phosphorylated by the EphrinB2 coexpressed by these cells in an autocrine or paracrine manner, or alternately, overexpression itself may result in constitutive activity (such as in RT4 cell line, which does not have any demonstrable EphrinB2 expression).
EphB4 expression is regulated by EGFR signaling and p53 expression EGFR is commonly expressed in bladder cancers (Chow et al., 2001 ) and appreciable expression was observed in six of nine (67%) bladder cancer cell lines (Figure 1a , fourth panel) and 11/15 (73%) tumor specimens ( Figure 1c , second panel) studied in this report. Activation of EGFR provides growth and survival signals to tumor cells. In an attempt to determine if EGFR signaling regulates expression of EphB4, we used an EGFR-specific kinase inhibitor (AG 1478). A dosedependent decline in EphB4 expression was observed following treatment of 5637 cells, which express EGFR. A 67% decline in EphB4 levels was seen following treatment for 24 h with 1 mM AG1478 (Figure 2a , left panel, summary of two independent experiments). AG-1478 had no effect on EphB4 levels in the EGFRnegative TCCSUP cell line (Figure 2a, right panel) . p53 mutation and loss of function is implicated in bladder cancer (Esrig et al., 1994 (Cooper et al., 1994; Rieger et al., 1995) . EphB4 expression declined by nearly 60% in positively selected cells (experiments repeated in triplicate), while no change was observed in cells transfected with empty vector (Figure 2b ). These results suggest that p53 regulates EphB4 expression either directly or via downstream effects.
EphB4 functions as a cell survival factor and is involved in cell growth and apoptosis To define the biological significance of the overexpression of EphB4, we studied 5637 cells, which express relatively high levels of EphB4. Targeted knockdown of EphB4 was achieved by potent EphB4-specific antisense ODN (Figure 3c ) or siRNA molecule (Figure 3f ). EphB4-specific siRNA inhibited cell growth and viability in 5637 cells in a dose-dependent manner with an 80% reduction in cell viability with 100 nM EphB4-specific siRNA at 48 h (Figure 3a , upper left panel). A less marked effect was observed in J82 cells that express low levels of EphB4, with a 35% reduction in viability at 48 h with 100 nM siRNA (Figure 3a , upper center panel). EphB4-specific siRNA had no effect on SLK cells (Figure 3a , upper right panel) that lack EphB4 expression ( Figure 3c ). Similarly, knockdown of EphB4 by antisense ODN significantly inhibited cell growth and viability in a dose-dependent manner in 5637 cells with a smaller effect in J82 cells, and had no effect on SLK cells EphB4 knockdown leads to decreased cell survival and increased apoptosis. A total of 1 Â 10 4 5637 (left panels), J82 (central panels) and SLK cells (right panels) were plated in each well of a 48-well plate and transfected with EphB4-specific siRNA or GFP siRNA. Cell viability was assessed by MTT assay and the average survival in three independent experiments expressed as percentage of absorbance relative to untreated cells (a, top panels). Cells were also treated with varying doses of EphB4-specific antisense ODN (AS-10M) or scrambled ODN (a, lower panels) for 5 days. In parallel experiments, 5637 cells were treated with EphrinB2-specific siRNA. EphrinB2 levels were assessed in 48 h by Western blotting to confirm knockdown of expression (b, top panel). Cell viability was assessed by MTT assay (b, bottom panel). 5637 cells were treated for 48 h with 10 mM AS-10M or scrambled ODN (S) and EphB4 levels assessed by Western blotting (c). Lysates of HUVE and SLK cells were loaded as positive and negative controls for EphB4 expression, respectively. 5637 cells were treated with test compounds at indicated dose levels and were examined in triplicate experiments for cytoplasmic nucleosomes as an index of apoptosis (d). Caspase-8 and -9 activation following EphB4 siRNA or GFP siRNA transfection was measured in duplicate to determine the site of initiation of apoptosis. Results are expressed as percent activity compared to control cells (e). 5637 cells were transfected with 50 nM EphB4-specific or control siRNA (GFP) for 48 h. Cell lysates (20 mg) were analysed by Western blotting for levels of various antiapoptotic proteins, bcl-xl, bcl-2 and mcl-1. EphB4 knockdown was confirmed by Western blotting and membranes were probed for b-actin to document equal load and transfer of proteins (f).
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G Xia et al ( Figure 3a , lower panels). Unrelated siRNA directed against green fluorescent protein (GFP) or scrambled ODN had no effect. IC 50 for siRNA and antisense ODNs in 5637 cells were approximately 40 nM and 5 mM, respectively. These results represent the mean from three independent experiments. In order to determine the role played by EphrinB2, the ligand for EphB4, in EphB4-mediated cell survival, we studied the effect of knockdown of EphrinB2 using siRNA ( Figure 3b , top panel). Despite near-complete abrogation of EphrinB2 expression, there was a minimal reduction (15%) in cell viability and survival at 48 h ( Figure 3b , bottom panel), suggesting the contribution of ligand-independent mechanism(s) of EphB4 signaling in modulating cell survival.
The reduction in cell viability on EphB4 knockdown was associated with an induction in apoptosis. EphB4 knockdown led to a dose-dependent accumulation of cytoplasmic nucleosomes ( Figure 3d ). This was associated with a predominant activation of caspase 8, or extrinsic apoptotic pathway ( Figure 3e ). For example, 100 nM EphB4 siRNA led to an 80% reduction in cell viability, 12-fold increase in cytoplasmic nucleosomes and 14-fold induction in caspase-8 activity. We also examined the status of antiapoptotic proteins including bcl-2, bcl-xl and mcl-1 after treatment with siRNA. EphB4 knockdown led to downregulation of bcl-xl (Figure 3f ), which is expressed in high levels in 5637 cells, while it did not impact the expression levels of bcl-2 and mcl-1, both of which are expressed at very low levels ( Figure 3f ).
EphB4 facilitates bladder cancer cell migration and invasion
Tumor growth and metastasis is regulated in part by the ability of tumor cells to degrade surrounding matrix tissue and migrate. EphB4 upregulation may contribute to acquiring such a phenotype. We studied the effect of EphB4 downregulation with lower doses of antisense (5 mM) and siRNA (50 nM) molecules over a short duration of time (9 h) under conditions that did not result in significant apoptosis and cell death (data not shown). To study the effect of EphB4 on bladder cancer migration in vitro, we performed a wound-healing assay. When a wound was introduced into subconfluent 5637 cultures, cells progressively migrate and repopulate the area of the wound over the course of the next 9 h. EphB4 knockdown with 50 nM EphB4 siRNA or 5 mM antisense ODN before wounding deterred wound healing by 65% and 60%, respectively. No such change was observed with GFP siRNA or scrambled ODNs (Figure 4a , representative photomicrographs from three repeat experiments). Invasion of cells into surrounding tissue for metastases requires degradation of matrix proteins. We thus conducted experiments using the Boyden chamber model wherein 5637 cells were plated on top of inserts coated with Matrigel and placed in a double chamber. Cells treated with 50 nM EphB4 siRNA or 5 mM antisense ODNs had markedly reduced degradation of the matrix and thus, reduced migration by 78% and 73% over 12 h, respectively, across the barrier compared to untreated cells or cells treated with control compounds, including GFP siRNA and scrambled ODN (Figure 4b , representative photomicrographs from three repeat experiments).
EphB4 induces MMP-9 activity Matrix metalloproteinases (especially, MMP-2 and -9) are critical matrix-degrading proteins expressed by cancer cells as they invade through surrounding basement membrane and metastasize (Hara et al., 2001; Vasala et al., 2003) . In order to determine the mechanism by which EphB4 facilitates tumor cell migration and invasion, we studied the activity of matrix metalloproteinases by zymogram following EphB4 knockdown. Following a 24 h treatment of 5637 cells with 10 nM EphB4 siRNA, a 70% reduction in MMP-9 activity was observed (average of three independent experiments; Figure 4c ), while no change was observed in MMP-2 activity (data not shown). Unrelated GFP-siRNA had no effect on the activity of both enzymes. Thus, EphB4 regulates tumor cell migration at least in part by regulating MMP-9.
EphB4-specific antisense ODN inhibits growth of bladder cancer xenografts and complements the effect of the chemotherapeutic agent, Taxol Having established a role for EphB4 in tumor cell viability, migration and invasion in vitro, we next sought to determine if tumor cells grown in vivo show similar behavior in bladder cancer. To this end, we implanted 5637 cells subcutaneously in male BalbC athymic mice. Once tumors were established, treatment was started with daily administration of EphB4 AS-10 (10 mg/kg/ day) or diluent (PBS) intraperitoneally (12 tumors in each group). Over the course of the next 9 weeks, an 80% reduction in tumor volume was observed in AS-10 ODN-treated animals compared to animals in the control group (Figure 5a , Po0.01). Tumors were harvested at the conclusion of the study and examined for changes in the target protein levels by Western blotting. EphB4 protein levels were reduced by 56% in EphB4 antisense-treated mice compared to controls by Western blotting (Figure 5a, inset) . In order to exclude the nonspecific effects of CpG nucleotides present in the antisense molecule studied, we generated two additional molecules -AS-10 with the cytosine base at the CpG site methylated (designated AS-10M) and a scrambled ODN with one CpG site and containing the same base composition as AS-10. We then tested these two molecules on tumor-bearing mice (n ¼ 8 in each group; Figure 5b ). While treatment with scrambled ODN had no effect on tumor volumes compared to vehicle-treated animals, AS-10M at a dose of 10 mg/kg resulted in 70% reduction in tumor volume, which is comparable to the effect seen with the unmethylated molecule. Similarly, tumor weights at harvest were 75% less in the antisensetreated animals compared to vehicle-treated animals, while there was no difference in tumor weights between vehicle-treated and scrambled ODN-treated animals ( Figure 5b , right top panel). In addition, we studied TNF-a and IL-12 levels in blood samples of mice in the various treatment groups and no changes were observed (data not shown). At the time of killing, spleens were harvested from mice in all treatment groups and evaluated. The spleen weights were comparable between the three groups ( Figure 5b , right bottom panel) and histologic examination revealed no change (data not shown). Whereas EphB4 levels fell by 54% in AS-10M-treated tumors (Figure 5b inset) , no change was observed in scrambled ODN-treated tumors. These results confirm that the observed reduction in tumor growth with EphB4-specific antisense ODN is a direct effect of targeted EphB4 knockdown and not mediated by pleiotropic cytokine responses.
Histological evaluation of the harvested tumors showed that tumors in AS-10-treated animals had large areas of central necrosis in comparison to vehicletreated or scrambled ODN-treated animals (Figure 5d , upper panels). In addition, EphB4 AS-10 ODN treatment reduced cell proliferation as measured by Ki-67 index by 70%, increased apoptosis sevenfold and reduced CD31-positive microvascular density by 65% (Figure 5b ). Treatment with scrambled ODN had no effect on any of these parameters.
To confirm the potential application of EphB4 knockdown as a clinical strategy to complement current treatment modalities available for bladder cancer, we performed additional experiments comparing the effect of the chemotherapeutic agent Taxol with AS-10M and their combination. Four groups of mice (n ¼ 8 per group) were implanted subcutaneously with 5 Â 10 6 5637 cells in the flanks. Beginning from day 4 after implantation, mice were treated daily with vehicle, intravenous Taxol (15 mg/kg), intraperitoneal AS-10M (10 mg/kg) or a combination of both (Figure 5c ). While treatment with Taxol alone resulted in 73% reduction in tumor volumes, treatment with AS-10M resulted in 85% reduction. A combination of the two compounds was more effective than either alone with a 95% reduction in Expression of EphB4 in bladder cancer G Xia et al tumor (P ¼ 0.01 compared to AS-10 alone, Po0.0001 compared to Taxol alone and vehicle). Thus, EphB4 knockdown effectively complements available chemotherapeutic strategies for bladder cancer. In order to determine if the observed tumor reduction could be sustained over time, drug administration was stopped after 6 weeks and tumors were evaluated for an additional 3-week period (area outside the shaded box in Figure 5c ). Despite withdrawal of the agents, no change was observed in the reduced growth rates of the tumors. Thus, specific inhibition of EphB4 expression results in marked inhibition of tumor growth alone and has additive effect when combined with cytotoxic chemotherapy.
Discussion
EphB4 is expressed in all bladder cancer cell lines examined and variations in the levels of expression may have implications on the behavior of the tumor cell line.
Receptor expression was validated in a preliminary study of freshly collected tumor specimens as well.
Overexpression of EphB4 has been documented in other epithelial cancer types, including breast cancer (Berclaz et al., 1996) , uterine caner (Berclaz et al., 2003) , prostate cancer (Xia et al., 2005b) and mesothelioma (Xia et al., 2005a) . Ours is the first report of EphB4 overexpression in bladder cancer. Frequent expression of EphB4 in bladder cancer combined with gene amplification Figure 5 EphB4 antisense ODN inhibits tumor growth in vivo. A total of 5 Â 10 6 5637 cells were implanted in the flanks of 10-to 12-week-old, male BalbC athymic mice (n ¼ 12 per group) and tumor volume measured (a) as detailed in the Materials and methods. EphB4 antisense ODN (AS-10 at 10 mg/kg) or equal volume of PBS was administered intraperitoneally daily starting day 4 after cell implantation. Animals were killed 9 weeks later and tumors harvested. Tumor lysates (20 mg) were analysed by Western blot for EphB4 and b-actin levels (a, inset). In other experiments, tumor-bearing mice (n ¼ 8 per group) were treated with scrambled ODN and CpG methylated AS-10M (b). Tumors (b, right upper panel) and spleens (b, right lower panel) were harvested and weighed. Western blot analysis for EphB4 and b-actin levels in harvested tumors is shown as inset in (b). The effect of combination therapy was evaluated by treating tumor-bearing mice (n ¼ 8 per group) with twice weekly intravenous Taxol (15 mg/kg) or daily intraperitoneal AS-10M (10 mg/ kg) or a combination of both. Treatment was discontinued at 6 weeks (shaded area) and tumor volumes measured for an additional 3 weeks. (c) Histological examination was performed on formalin-fixed paraffin-embedded tumor tissues (d, upper panel) and immunohistochemical analysis was carried out for Ki-67 and CD31 expression (d, lower panels). Apoptosis was evaluated in situ by TUNEL assay. Number of cells staining positive was averaged over five random high-power fields by a blinded observer and is shown below representative photomicrographs.
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suggests that EphB4 may have a biological significance in bladder cancer. Knockdown of expression with siRNA leads to loss of tumor cell viability, and induction of apoptosis via activation of caspase 8, leaving little doubt that EphB4 is functionally important in bladder cancer, an observation further strengthened by the use of nucleic acid-based therapeutics in vivo. These results suggest that EphB4 might be important in other cancer types where it is expressed as well. Given the lack of correlation between EphB4 mRNA and protein levels, documentation of protein expression using specific reagents with high sensitivity therefore, becomes particularly significant. In this study, we have used monoclonal antibodies that are highly sensitive and provide specific signals on Western blotting and immunofluorescence. On Western blotting, 93% tumor tissues expressed EphB4 protein, while adjacent normal urothelium had little or no EphB4 (Figure 1c) . Using a commercially available polyclonal antibody directed against the C-terminal of EphB4, only 53% had a detectable signal with immunohistochemistry ( Figure 1d ), a difference we believe represents differences in sensitivities of the antibodies. Along these lines, there is some controversy in the literature regarding expression of EphB receptors in human cancers. While several prior reports document overexpression of EphB2 and EphB4 in colorectal cancers (Stephenson et al., 2001; Mao et al., 2004) , a recent report by Battle et al. (2005) , for example, suggests that human colorectal cancers lose expression of EphBs at the adenomacarcinoma transition and that this loss strongly correlates with degree of malignancy. They evaluated EphB4 expression on sections using a C-terminal polyclonal antibody that appears to provide a low signal based on the prolonged incubation time of 4 days in the published papers. Resolution of these contradictory findings will require the use of reagents with high specificity and sensitivity, and more significantly, a study of the biological outcome of the knockdown of EphB2 and EphB4 using effective methods such as siRNA or antibodies.
EPHB4 gene locus amplification correlates with elevated EphB4 protein levels, implicating gene amplification in EphB4 overexpression. However, given that gene amplification was identified in less than a fourth of the cases, other mechanisms that regulate EphB4 expression must be operative. We address this issue in part by examining the role of the tumor suppressor gene p53, which is commonly mutated in invasive bladder cancer. Indeed, p53 regulates EphB4, as the introduction of wild-type protein in a p53 mutant cell line reduced EphB4 levels (Figure 2b) . The mechanism by which p53 regulates EphB4 has not yet been defined. Wild-type p53 interacts with several signaling pathways that provide survival signals to cells, including the PI3K and MAPK pathways. Preliminary data from our laboratory suggest that signaling via PI3K/akt pathway induces EphB4 expression. It is thus likely that loss-of-function mutation in p53 leads to activation of Akt and thus induces EphB4 expression. Bladder cancer is also regulated by several growth factors, including EGF/EGFR. EGFRspecific kinase inhibitor treatment reduces EphB4 levels in cell lines expressing EGFR with no effect on cells that lack EGFR expression (Figure 2a) . EGFR signaling antagonizes Notch signaling (Hasson et al., 2004) . We and others have shown that Notch signaling upregulates EphrinB2 expression and reciprocally downregulates EphB4 levels (Lawson et al., 2001 ; unpublished personal data), thereby providing a potential mechanism by which EGFR controls EphB4 expression. These results raise several questions that need to be addressed in future studies. What role do other members of erbB family of receptors play in regulating EphB4 expression and function? Is there complementary interaction between p53 and EGF/EGFR in regulating EphB4 expression and function?
EphB4 has biological effects in bladder tumor cells. Firstly, EphB4 receptor is functional as demonstrated by ligand-induced phosphorylation (Figure 1b) , combined with ligand expression in bladder cancer cell lines and tumor specimens (Figure 1a and c) . It is therefore likely that EphrinB2 expressed on bladder cancer cells stimulates EphB4 in a paracrine or autocrine manner. Consistent with this hypothesis, cell lines that coexpress the receptor and ligand when cultured in serumrich environment, express basal levels of receptor phosphorylation in the absence of exogenous ligand supplementation. In addition, a recent report by Noren et al. (2004) documented that tumor cell expressed EphB4 could also interact with endothelial EphrinB2. The RT24 cell line that had no detectable EphrinB2 expression, but high levels of EphB4, also had basal receptor phosphorylation, implicating a role for ligand-independent signaling by EphB4. While the exact nature of such pathways is currently not known, we believe that receptor overexpression leads to constitutive activity, analogous to that seen with other receptor tyrosine kinases such as erbB2 (Di Fiore et al., 1990) .
We next wished to determine if EphB4 expression provides a beneficial function to bladder cancer cells. Tumor metastasis is dependent on the ability of tumor cells to invade normal tissues. We have shown that bladder cancer cells can effectively invade a matrix barrier in vitro, and this ability is markedly diminished when EphB4 expression is inhibited by siRNA (Figure 4b ). EphB4 knockdown leads to diminished MMP-9 activity (Figure 4c ), an effect that could underlie the observed reduction in tumor cell migration and invasion following EphB4 knockdown. Such an effect of EphB4 on cell migration can be expected based on the established role of EphB4 in pattern formation and cell migration in endothelial cells and in neuronal cells in the central nervous system (Holder and Klein, 1999; Tickle and Altabef, 1999) . Also, targeted mammary overexpression of EphB4 in NeuT transgenic mice results in metastatic breast cancer, while in the absence of EphB4 overexpression, animals uniformly have organ-confined tumors (Munarini et al., 2002) . Our results therefore shed light on the mechanism by which EphB4 affords a malignant and invasive phenotype to cancer cells.
Other important attributes of tumor cells are the capacity to self-renew or fail to undergo cell death. Importantly, loss of EphB4 results in cell death via apoptosis (Figure 3a and d) . Furthermore, cell death is induced by events occurring at the cell membrane, where death receptor activation leads to activation of caspase 8 (Figure 3e ). The next obvious question is the process by which EphB4 inhibits death receptor pathways. This could occur by a reduction in the expression of death receptors, their ligands or an increase in proteins that inhibit caspase activation. These events may also occur via downstream signaling effects of activated EphB4 or by physical interaction and interference with death receptor pathways. Knockdown of endogenous EphrinB2 expression with siRNA did not impact cell survival (Figure 3b) , implying that alternative pathways of EphB4 signaling are also operational in providing survival cues to tumor cells. In order to gain a comprehensive view of the effects of EphB4 on apoptosis, we also examined changes in the levels of the bcl-2 family of proteins, which are antiapoptotic in nature (Figure 3f ). We noticed that bcl-xl is expressed at high levels in bladder cancer cell lines and its levels decline upon depletion of EphB4 using siRNA. Thus, it appears that EphB4 regulates cell survival by targeting several proteins in the apoptotic pathway.
Based on these studies in vitro, we expected that inhibition of EphB4 expression would lead to inhibition of tumor growth in vivo. Antisense ODNs that replicate the effects of siRNA in vitro were used to inhibit gene expression in vivo, given that these compounds are more suitable for studies in vivo in contrast to siRNA, which are highly unstable and difficult to deliver systemically to tumor cells. EphB4 knockdown by antisense ODNs showed a dramatic decrease in growth of tumors in mice bearing bladder cancer xenografts (Figure 5a ). We excluded nonspecific cytokine-mediated effects by studying scrambled ODNs, which had no effect, and antisense ODNs with the cytosine residue at the CpG site methylated, which were as potent as the unmethylated ODNs (Figure 5b ). In addition, there was no demonstrable induction of cytokines in mice treated with ODNs. Antisense ODN treatment specifically decreased levels of EphB4 in tumors (inset in Figures 5a and b) . Also, several biomarkers examined showed correlation with effects observed in vitro, such as reduced tumor proliferative indices and induction of apoptosis in tumor cells (Figure 5d ). EphB4 knockdown also significantly reduced tumor microvascular density, likely due to reduced stimulation of EphrinB2 expressed on tumor endothelial cells (Noren et al., 2004) . It is therefore possible that targeting EphB4 in vivo inhibits tumor growth by two distinct and complementary mechanisms -direct inhibition of cell survival and indirect antiangiogenic effects. Alternatively, the angiogenic phenotype of the tumor cells may be grossly altered by downregulation of EphB4. To further establish a role for EphB4 knockdown as a strategy for clinical application in bladder cancer, we studied the combined effect of Taxol, a chemotherapeutic agent commonly used in bladder cancer, and EphB4-specific antisense molecule. EphB4 knockdown effectively complements chemotherapy (Figure 5c ). Interestingly, following cessation of therapy with AS-10M, tumor growth did not change for a period of 3 weeks. It is conceivable that this persistent effect results from sustained loss of EphB4-overexpressing clones of cells from the tumors following antisense therapy.
In summary, we demonstrate that functional EphB4 is expressed in bladder cancer cells and is regulated via distinct pathways including gene amplification, growth factor signaling through EGFR, and through p53 function. EphB4 mediates cell survival by inhibiting the extrinsic apoptotic pathway, and affords an invasive phenotype -properties that can be effectively reversed by targeted EphB4 disruption. EphB4 is thus a potential candidate as a predictor of disease outcome in bladder cancer and importantly as a target for novel therapies in advanced disease not amenable to current treatment approaches.
Materials and methods

Reagents
Anti-EGFR, EphB4 (C-16), CD31 (M20), EphrinB2 (P20) and p53 (FL-393) antibodies were from Santa Cruz Biotech (Santa Cruz, CA, USA) and anti-human Fc was from Jackson Labs (Bar Harbor, ME, USA). Monoclonal antibodies against Bcl-2 and Bcl-xl were from Calbiochem (San Diego, CA, USA), Mcl-1 from BD PharMingen (San Diego, CA, USA), Ki-67 from DAKO (Carpentaria, CA, USA), anti-phosphotyrosine (clone 4G10) from Upstate (Lake Placid, NY, USA) and b-actin from Sigma Chemical Co. (St Louis, MO, USA). Monoclonal EphB4 antibodies used in immunoprecipitation (Clone #47) and Western blotting (Clone #265) were from VasGene Inc. (Los Angeles, CA, USA). Media and FBS were from Invitrogen (Carlsbad, CA, USA). AG 1478 (4-(3 0 -chloroanilino)-6,7-dimethoxy-quinazoline) was from Calbiochem (San Diego, CA, USA). EphrinB2/Fc chimeric protein was from R&D Systems Inc. (Minneapolis, MN, USA) and human IgG Fc fragment was from Jackson Labs.
Cell lines and culture T24, TCCSUP, UMUC-3, J82, RT4, 5637, LD611, HT1376 and LD605 were obtained and cultured as described previously (Wu et al., 2003) . Kaposi's sarcoma cell line (SLK) was obtained from ATCC and human umbilical venous endothelial cells were from Clonetics (San Diego, CA, USA) and were maintained as described previously (Masood et al., 2005) .
Human bladder and bladder cancer tissues A total of 15 paired specimens of transitional cell carcinoma and adjacent normal bladder tissue were obtained from cystectomy specimens at surgery undertaken with curative intent. Specimens were obtained fresh from the dissected specimen and snap-frozen in liquid nitrogen for later analysis. Collection of this material was undertaken with the approval of the USC Institutional Review Board and after acquisition of written informed consent from each patient.
Western blot
Protein from cultured cells and tumor samples was extracted using Cell Lysis Buffer (GeneHunter, Basgvukke, TN, USA) supplemented with protease inhibitor cocktail (Pierce, Rockford, IL, USA). Total protein was determined using the DC reagent system (Bio-Rad, Hercules, CA, USA). Typically, 20 mg of protein of whole-cell lysate was run on 4-20% Trisglycine gradient gel. The samples were electro-transferred to a PVDF membrane and nonspecific binding was blocked in TBST buffer (0.5 mM Tris-HCl, 45 mM NaCl, 0.05% Tween 20, pH 7.4) containing 5% nonfat milk. Primary antibody incubation was performed at 41C overnight. Membranes were then washed, and probed with appropriate secondary antibodies for 1 h at room temperature. Signal was detected using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce, Rockford IL, USA). When indicated, the same membrane was stripped with Restoret Western Blot stripping buffer (Pierce, Rockford, IL, USA) and reprobed with b-actin to confirm equivalent loading and transfer of protein.
Gene amplification study Primers for gene amplification were designed with Primer3 with the products spanning an exon-intron junction. The sequences are as follows: EphB4-forward: 5 0 -TCC TGC AAG GAG ACC TTC AC-3 0 ; EphB4-reverse: 5 0 -CAG AGG CCT CGC AAC TAC AT-3 0 ; GAPDH-forward: 5 0 -GAG GGG TGA TGT GGG GAG TA-3 0 and GAPDH-reverse: 5 0 -GAG CTT CCC GTT CAG CTC AG-3 0 . DNA was extracted from peripheral blood monocytes (PBMCs) of a normal donor and the bladder cancer cell lines and tumor samples using the Blood and Cell Culture DNA Midi kit from Qiagen according to the manufacturer's instructions. Quantitative PCR was performed on 50 ng of DNA on the Stratagene MX3000P system (Stratagene, La Jolla, CA, USA) using SYBR Green I Brilliant Mastermix (Stratagene) according to the manufacturer's instructions. The thermal profile was 951C for 10 min followed by 40 cycles of 951C for 30 s, 641C for 1 min and 721C for 1 min. The specificity of amplification was confirmed by the presence of a single dissociation peak. All the reactions were performed in triplicate with no template as negative controls. Amplification signal for EphB4 was normalized to GAPDH signal and calibrated to PBMCs to derive the gene copy number.
Immunohistochemistry
Frozen sections (5 mm) were fixed in 4% phosphate-buffered methanol (pH 7.4) and blocked with SuperBlock blocking buffer (Pierce, Rockford, IL, USA). Sections were then incubated with EphB4 (C-16) antibody (1:50) or CD31 (1:200) antibody for 1 h at room temperature followed by three washes in PBS and incubation with donkey anti-goat secondary antibody (Santa Cruz Biotech) for 1 h at room temperature. After three washes in PBS, peroxidase activity was localized by incubation in DAB substrate solution (Vector Laboratories Inc., Burlingame, CA, USA) for 10 min at room temperature. Sections were counterstained with hematoxylin for 45 s. Substitution of normal IgG isotope for primary antibody was used as a negative control. Immunohistochemical staining on the formalin-fixed tissues of in vivo study was carried out using ABC Staining System (Vector Laboratories Inc.) according to the manufacturer's instructions. Prior to staining, antigen epitope retrieval was performed by boiling slides in 10 mM sodium citrate buffer (pH 8.5) at 801C for 20 min. The antibody dilutions were CD31 (1:200) and .
Phosphorylation studies 5637 cells grown to 80% confluence were serum starved overnight. Ephrin B2-Fc or Fc was clustered by incubating with 1:1000 dilution anti-human Fc antibody for 1 h at 41C. Protein (3 mg/ml) was then added to the supernatant for the duration specified to activate EphB4 receptor. Cleared cell lysates (100 mg) were incubated with 2 mg/ml EphB4 monoclonal antibody (Clone #47) overnight at 41C. Antigenantibody complexes were immunoprecipitated by shaking with 10 ml of Protein A/G-Sepharose (Santa Cruz Biotech, Santa Cruz, CA, USA) for 2 h at 41C. Immunoprecipitates were immunoblotted with anti-phosphotyrosine antibody to detect phosphorylation status. To monitor immunoprecipitation efficiency, a duplicate membrane was probed with EphB4-specific monoclonal antibody. In order to determine phosphorylation levels in the absence of exogenous ligand, various bladder cancer cells were grown to 80% confluence in the presence of serum-containing medium. Protein was extracted from cells as detailed above and EphB4 immunoprecipitated in a similar fashion.
Study of EGFR signaling pathway
Cells were cultured in a six-well plate until 80% confluent. Cells were treated with EGFR kinase inhibitor, AG1478 in fresh medium at 0.25, 0.5 and 1 mM for 24 h. Crude cell lysates were analysed by Western blot.
Cell transfection studies 5637 cells were cultured in a 10 cm 2 dish until 80% confluent. Cells were cotransfected with pMACS 4.1 coding for a truncated CD4 and wild-type p53 (pC53-SN 3 ) or empty vector using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The molar ratio of CD4 to p53 or vector was 1:3 and total plasmid was 24 mg using 60 ml of Lipofectamine 2000. At 24 h after transfection, a single-cell suspension was made and sorted using truncated CD4 as a surface marker according to the manufacturer's protocol (Miltenyi Biotec, Germany). Sorted cells were lysed in 1 Â SDS sampling buffer and 20 mg protein was loaded for Western blot.
ODNs and siRNAs EphB4-specific antisense phosphorothioate-modified ODN and scrambled ODN were synthesized and purified by Qiagen (Valencia, CA, USA). The antisense ODN used, AS-10, spanned nucleotides 1980-1999 with a sequence 5 0 -ATG-GAG-GCC-TCG-CTC-AGA-AA-3 0 . For use in vivo, the cytosine in position 11 was methylated (AS-10M). Scrambled ODN containing random nucleotide sequence 5 0 -TAC CTG AAG GTC AGG CGC AC-3 0 was used as a control. siRNAs were synthesized at the USC/Norris Comprehensive Cancer Center Microchemical Core Laboratory. EphB4 siRNA corresponding to the sequence 5 0 -CCGGGAAGGUGAAU GUCAA-3 0 and EphrinB2 siRNA corresponding to 5 0 -GCAGACAGAUGCACUAUUAUU-3 0 were used for RNA interference. siRNA against GFP with sequence 5 0 -CGCU GACCCUGAAGUUCATUU-3 0 was used as a negative control.
Cell viability assay Cells were seeded on 48-well plates at a density of approximately 1 Â 10 4 cells/well in a total volume of 200 ml. Media were changed after 1 day and cells were treated with various concentrations (1-10 mM) of EphB4 antisense ODN or scrambled ODN as control. After 3 days, media were changed and fresh ODNs were added. Following further 48 h incubation, cell viability was assessed by MTT assay as described (Masood et al., 2003) . Test siRNAs or GFP siRNA (10-100 nM) were introduced into 2 Â 10 4 cells/well of a 48-well plate using 2 ml of Lipofectamine 2000. At 6 h post-transfec-tion, cells were returned to growth media and viability was assayed by MTT 48 h following transfection.
Apoptosis study
Apoptosis was studied in vitro using the Cell Death Detection ELISAplus Kit (Roche, Piscataway, NJ, USA) according to the manufacturer's instructions. Briefly, 80% confluent 5637 cells cultured in 24-well plates were transfected using Lipofectamine 2000 with various concentrations (0-100 nM) of EphB4 siRNA or GFP siRNA. Cells were detached after 16 h and 1 Â 10 4 cells were incubated in 200 ml lysis buffer. Nuclei were pelleted by centrifugation and 20 ml of supernatant containing the mono-or oligonucleosomes was taken for ELISA analysis. Briefly, the supernatant was incubated with anti-histone-biotin and anti-DNA-POD in a streptavidincoated 96-well plate for 2 h at room temperature. Color was developed with ABST and absorbance at 405 nm was read in a microplate reader (Molecular Devices, Sunnyvale, CA, USA). Apoptosis in deparaffinized sections of tumor tissue from murine xenograft studies was detected using the in situ cell death detection kit (Roche) according to the manufacturer's instructions.
Caspase-8 and -9 activity analysis Caspase activity was measured by colorimetric assay (R&D systems Inc., Minneapolis, MN, USA) according to the manufacturer's instructions. Briefly, 5637 cells were transfected with EphB4 siRNA or GFP siRNA (50 nM) and after 24 h, cell lysates were incubated with reaction buffer and the appropriate colorimetric substrate at 371C for 2 h. Color development was quantified by measuring absorbance at 405 nm. Routine controls included deletion of cell lysate or substrate.
Wound healing migration assay 5637 cells were seeded into six-well plates and cultured until confluent. Cells were treated with AS-10 or scrambled ODN (5 mM) 12 h before wounding the monolayer by scraping it with a sterile pipette tip. Medium was changed to RPMI 1640 supplemented with 5% FBS and fresh ODNs. The healing process was examined dynamically over the next 9 h and recorded with a Nikon Coolpix 5000 digital camera with microscope adapter. The same analysis was performed with confluent cultures transfected with 50 nM EphB4 siRNA or GFP siRNA 12 h prior to wounding. Three different areas were chosen each time and experiments were repeated three times.
Invasion assay 5637 cells were transfected with EphB4 siRNA or GFP siRNA (50 nM) using Lipofectamine 2000, and 6 h later, 0.5 Â 10 5 cells were transferred into 8 mm Matrigel-pre-coated inserts (BD Bioscience, Palo Alto, CA, USA). The inserts were placed in companion wells containing RPMI supplemented with 5% FBS and 5 mg/ml fibronectin as a chemoattractant. Following 20 h incubation, the inserts were removed and the noninvading cells on the upper surface were removed with a cotton swab. The cells on the lower surface of the membrane were fixed in 100% methanol for 15 min, air dried and stained with Giemsa stain for 2 min. The cells were counted in five individual highpowered fields for each membrane under a light microscope. Assays were performed in triplicate for each treatment group. Same assays were repeated with EphB4 AS-10, AS-10M and scrambled ODNs.
Gelatin zymography 5637 cells were cultured until 80% confluent. Cells were transfected with GFP siRNA or EphB4 siRNA (50 nM) and cultured for 24 h. Conditioned medium from equal cell numbers was collected, concentrated 100-fold and electrophoresed through a 10% zymogram gel (Criterion Zymogram, BioRad, CA, USA). The gel was washed three times for 1 h with 2.5% Triton X-100 to remove the SDS, and incubated for 24 h at 371C in collagenase buffer containing 50 mM Tris, 200 mM NaCl and 10 mM CaCl 2 , pH 7.5. Gelatinolytic activity was visualized by staining the gel in 0.5% Coomassie blue.
In vivo tumor growth studies 5637 cells were propagated, collected by trypsin digestion and resuspended in serum-free medium. A total of 5 Â 10 6 cells were injected in the flanks in 10-to 12-week-old, male BalbC athymic mice. Tumor growth was measured every other day and volume estimated as 0.52 Â a Â b 2 , where a and b are the largest and smallest lengths of the palpable tumor. On day 5 after cell implantation, tumor volumes were calculated to ensure uniformity in size and animals were randomly divided into two groups (12 mice per group). Each group was administered daily by intraperitoneal injection oligo-EphB4 AS-10 at a dose of 10 mg/kg or vehicle alone (PBS). Animals were killed and tumors and normal organs harvested at the completion of the studies. A portion of the tumors was fixed in formalin for paraffin embedding and histologic analysis. The remaining tumor tissue and organs in each group were pooled and protein extracted for immunoblotting. To control for cytokine responses, the same experiment was repeated using methylated antisense molecule (AS-10M) and scrambled ODN at 10 mg/kg dose. In order to study the combined effect of chemotherapeutic agents and AS-10M, tumor-bearing mice were treated by twice weekly intravenous injection of Taxol (15 mg/kg) or daily intraperitoneal AS-10M (10 mg/kg) or a combination of both. Following 6 weeks of treatment, all agents were withdrawn and tumor volumes measured for an additional 3-week period. All procedures were approved by our Institutional Animal Care and Use Committee and performed in accordance with the Animal Welfare Act regulations.
Statistical analyses
Data are presented as mean7s.e.m. Band intensity after electrophoresis was evaluated using ImageJ software (version 1.32j) from National Institutes of Health, Maryland and normalized to b-actin. Extent of repopulation by cancer cells in migration study was also evaluated with this software. Differences in tumor volume in vivo and number of cells staining positive were analysed by Student's t-test and significance was set at Po0.05.
